(PNTG) Pennant - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.179m USD | Total Return: 19.7% in 12m

Home Health, Hospice Care, Senior Living
Total Rating 54
Safety 61
Buy Signal -0.09
Medical Care Facilities
Industry Rotation: +6.5
Market Cap: 1.18B
Avg Turnover: 7.18M
Risk 3d forecast
Volatility38.3%
VaR 5th Pctl6.58%
VaR vs Median4.36%
Reward TTM
Sharpe Ratio0.60
Rel. Str. IBD70.8
Rel. Str. Peer Group80.6
Character TTM
Beta0.680
Beta Downside0.463
Hurst Exponent0.475
Drawdowns 3y
Max DD40.16%
CAGR/Max DD1.08
CAGR/Mean DD2.76
EPS (Earnings per Share) EPS (Earnings per Share) of PNTG over the last years for every Quarter: "2021-03": 0.11, "2021-06": 0.17, "2021-09": 0.11, "2021-12": 0.07, "2022-03": 0.1, "2022-06": 0.14, "2022-09": 0.14, "2022-12": 0.18, "2023-03": 0.13, "2023-06": 0.18, "2023-09": 0.2, "2023-12": 0.22, "2024-03": 0.2, "2024-06": 0.24, "2024-09": 0.26, "2024-12": 0.24, "2025-03": 0.27, "2025-06": 0.27, "2025-09": 0.17, "2025-12": 0.34, "2026-03": 0.32,
EPS CAGR: 20.90%
EPS Trend: 95.2%
Last SUE: 0.23
Qual. Beats: 0
Revenue Revenue of PNTG over the last years for every Quarter: 2021-03: 105.663, 2021-06: 110.345, 2021-09: 111.921, 2021-12: 111.765, 2022-03: 113.91, 2022-06: 116.316, 2022-09: 118.35, 2022-12: 124.665, 2023-03: 126.464, 2023-06: 132.281, 2023-09: 140.192, 2023-12: 145.954, 2024-03: 156.915, 2024-06: 168.745, 2024-09: 180.688, 2024-12: 188.892, 2025-03: 209.842, 2025-06: 219.501, 2025-09: 229.039, 2025-12: 289.323, 2026-03: 285.364,
Rev. CAGR: 29.67%
Rev. Trend: 99.4%
Last SUE: 0.84
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

Idiosyncratic Leader, Confidence

Description: PNTG Pennant

The Pennant Group, Inc. (PNTG) provides home health, hospice, and senior living services across 15 U.S. states. Operating through two primary segments, the company delivers clinical nursing, physical therapy, and end-of-life care, alongside residential senior living solutions that include assisted and independent living support. The business model utilizes a decentralized management structure, allowing local leaders to tailor clinical services to specific regional demographics.

The home health and hospice sector is characterized by a reimbursement landscape heavily influenced by Medicare and Medicaid policy shifts. As the U.S. population ages, demand for cost-effective, home-based clinical interventions continues to grow relative to traditional inpatient settings. Investors can utilize ValueRay to further analyze the companys valuation metrics and historical performance.

Headquartered in Eagle, Idaho, Pennant Group was incorporated in 2019 following a spin-off from The Ensign Group. Its current operations span the Western and Southeastern United States, focusing on a continuum of care that transitions patients from acute recovery to long-term residential support.

Headlines to Watch Out For
  • Medicare reimbursement rate adjustments directly impact home health and hospice revenue margins
  • Strategic acquisitions of underperforming senior living communities drive long-term portfolio growth
  • Labor market volatility and clinical staffing costs pressure operational bottom line
  • Aging demographic trends increase demand for specialized home-based clinical services
  • Regulatory changes in hospice oversight heighten compliance risks and audit exposure
Piotroski VR-10 (Strict) 5.0
Net Income: 30.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.78 > 1.0
NWC/Revenue: 2.37% < 20% (prev 4.80%; Δ -2.43% < -1%)
CFO/TA 0.07 > 3% & CFO 66.1m > Net Income 30.3m
Net Debt (724.7m) to EBITDA (67.1m): 10.81 < 3
Current Ratio: 1.19 > 1.5 & < 3
Outstanding Shares: last quarter (35.8m) vs 12m ago 1.58% < -2%
Gross Margin: 14.78% > 18% (prev 0.14%; Δ 1.46k% > 0.5%)
Asset Turnover: 120.4% > 50% (prev 100.6%; Δ 19.76% > 0%)
Interest Coverage Ratio: 6.77 > 6 (EBITDA TTM 67.1m / Interest Expense TTM 8.54m)
Altman Z'' 1.12
A: 0.03 (Total Current Assets 152.8m - Total Current Liabilities 128.6m) / Total Assets 956.5m
B: 0.10 (Retained Earnings 95.3m / Total Assets 956.5m)
C: 0.07 (EBIT TTM 57.8m / Avg Total Assets 850.1m)
D: 0.17 (Book Value of Equity 95.4m / Total Liabilities 567.0m)
Altman-Z'' = 1.12 = BB
Beneish M -2.78
DSRI: 0.95 (Receivables 122.8m/95.0m, Revenue 1.02b/748.2m)
GMI: 0.93 (GM 14.78% / 13.71%)
AQI: 1.22 (AQ_t 0.49 / AQ_t-1 0.40)
SGI: 1.37 (Revenue 1.02b / 748.2m)
TATA: -0.04 (NI 30.3m - CFO 66.1m) / TA 956.5m)
Beneish M = -2.78 (Cap -4..+1) = A
What is the price of PNTG shares?

As of May 27, 2026, the stock is trading at USD 33.92 with a total of 142,593 shares traded.
Over the past week, the price has changed by -4.02%, over one month by +9.81%, over three months by +11.25% and over the past year by +19.65%.

Is PNTG a buy, sell or hold?

Pennant has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold PNTG.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PNTG price?
Analysts Target Price 40.8 20.4%
Pennant (PNTG) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 1.18b (1.18b USD * 1.0 USD.USD)
P/E Trailing = 39.4419
P/E Forward = 25.3807
P/S = 1.1525
P/B = 3.4073
P/EG = 1.9539
Revenue TTM = 1.02b USD
EBIT TTM = 57.8m USD
EBITDA TTM = 67.1m USD
Long Term Debt = 164.7m USD (from longTermDebt, last quarter)
Short Term Debt = 30.6m USD (from shortTermDebt, last quarter)
Debt = 729.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 283.1m
Net Debt = 724.7m USD (calculated: Debt 729.6m - CCE 4.91m)
Enterprise Value = 1.90b USD (1.18b + Debt 729.6m - CCE 4.91m)
Interest Coverage Ratio = 6.77 (Ebit TTM 57.8m / Interest Expense TTM 8.54m)
EV/FCF = 40.22x (Enterprise Value 1.90b / FCF TTM 47.3m)
FCF Yield = 2.49% (FCF TTM 47.3m / Enterprise Value 1.90b)
FCF Margin = 4.63% (FCF TTM 47.3m / Revenue TTM 1.02b)
Net Margin = 2.96% (Net Income TTM 30.3m / Revenue TTM 1.02b)
Gross Margin = 14.78% ((Revenue TTM 1.02b - Cost of Revenue TTM 872.0m) / Revenue TTM)
Gross Margin QoQ = 13.10% (prev 12.93%)
Tobins Q-Ratio = 1.99 (Enterprise Value 1.90b / Total Assets 956.5m)
Interest Expense / Debt = 1.17% (Interest Expense 8.54m / Debt 729.6m)
Taxrate = 26.93% (3.79m / 14.1m)
NOPAT = 42.2m (EBIT 57.8m * (1 - 26.93%))
Current Ratio = 1.19 (Total Current Assets 152.8m / Total Current Liabilities 128.6m)
Debt / Equity = 2.11 (Debt 729.6m / totalStockholderEquity, last quarter 346.0m)
Debt / EBITDA = 10.81 (Net Debt 724.7m / EBITDA 67.1m)
Debt / FCF = 15.31 (Net Debt 724.7m / FCF TTM 47.3m)
Total Stockholder Equity = 328.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.57% (Net Income 30.3m / Total Assets 956.5m)
RoE = 9.23% (Net Income TTM 30.3m / Total Stockholder Equity 328.5m)
RoCE = 11.72% (EBIT 57.8m / Capital Employed (Equity 328.5m + L.T.Debt 164.7m))
RoIC = 4.95% (NOPAT 42.2m / Invested Capital 853.6m)
WACC = 5.50% (E(1.18b)/V(1.91b) * Re(8.37%) + D(729.6m)/V(1.91b) * Rd(1.17%) * (1-Tc(0.27)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 7.74%
[DCF] Terminal Value 77.97% ; FCFF base≈31.9m ; Y1≈36.6m ; Y5≈53.8m
[DCF] Fair Price = 2.45 (EV 809.7m - Net Debt 724.7m = Equity 85.0m / Shares 34.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.16 | EPS CAGR: 20.90% | SUE: 0.23 | # QB: 0
Revenue Correlation: 99.44 | Revenue CAGR: 29.67% | SUE: 0.84 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=+3.13% | Revisions=+33% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.34 | Chg30d=+0.85% | Revisions=+11% | Analysts=7
EPS current Year (2026-12-31): EPS=1.35 | Chg30d=+2.05% | Revisions=+60% | GrowthEPS=+14.6% | GrowthRev=+22.9%
EPS next Year (2027-12-31): EPS=1.59 | Chg30d=+1.45% | Revisions=+50% | GrowthEPS=+17.6% | GrowthRev=+7.8%
[Analyst] Revisions Ratio: +60%